Review
Biochemistry & Molecular Biology
Francesco Claps, Nicola Pavan, Luca Ongaro, Domenico Tierno, Gabriele Grassi, Carlo Trombetta, Gabriele Tulone, Alchiede Simonato, Riccardo Bartoletti, Laura S. Mertens, Bas W. G. van Rhijn, Maria Carmen Mir, Bruna Scaggiante
Summary: Urothelial carcinoma is a common type of cancer, with bladder carcinoma being the most prevalent form. For non-muscle-invasive bladder cancer that does not respond to BCG treatment, radical cystectomy is currently the standard treatment. However, this surgery carries high risks and impacts the patient's quality of life, highlighting the need for alternative bladder-preserving therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Urology & Nephrology
Cedric Lebacle, Yohann Loriot, Jacques Irani
Summary: The study summarized current and upcoming treatment options available for high-risk NMIBC patients experiencing BCG failure by the end of 2020. The critical definition of BCG unresponsive disease has been established, and promising alternatives to radical cystectomy are now available with more expected in the near future.
WORLD JOURNAL OF UROLOGY
(2021)
Review
Oncology
Camilla De Carlo, Marina Valeri, Devin Nicole Corbitt, Miriam Cieri, Piergiuseppe Colombo
Summary: This review summarizes the recent evidence on prognostic and predictive tissue biomarkers in non-muscle invasive bladder cancer (NMIBC), highlighting the importance of histological features and molecular events in predicting recurrence and progression. The review also emphasizes the potential of immunohistochemical evaluation as a cost-effective tool for clinical practice.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Wujun Chen, Ning Liu, Yang Yuan, Meng Zhu, Xiaokun Hu, Wenchao Hu, Shuai Wang, Chao Wang, Binghuan Huang, Dongming Xing
Summary: Bladder cancer (BCa) is a common malignancy that often leads to death. The majority of BCa cases develop into non-muscle-invasive bladder cancer (NMIBC). Bacillus Calmette-Guerin (BCG) is the standard treatment for NMIBC, but there is a significant portion of patients who do not respond to BCG. Some drugs, such as valrubicin and pembrolizumab, have been approved by the FDA for the treatment of BCG-unresponsive NMIBC, but their complete remission rates are not satisfactory. ALT-803, a new drug that promotes the proliferation and activation of certain immune cells, has shown promising clinical efficacy and safety compared to other treatments for BCG-unresponsive NMIBC.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, Neal D. Shore, Leonard G. Gomella, Ashish M. Kamat, Trinity J. Bivalacqua, Jeffrey S. Montgomery, Seth P. Lerner, Joseph E. Busby, Michael Poch, Paul L. Crispen, Gary D. Steinberg, Anne K. Schuckman, Tracy M. Downs, Robert S. Svatek, Joseph Mashni, Brian R. Lane, Thomas J. Guzzo, Gennady Bratslavsky, Lawrence I. Karsh, Michael E. Woods, Gordon Brown, Daniel Canter, Adam Luchey, Yair Lotan, Tracey Krupski, Brant A. Inman, Michael B. Williams, Michael S. Cookson, Kirk A. Keegan, Gerald L. Andriole, Alexander I. Sankin, Alan Boyd, Michael A. O'Donnell, David Sawutz, Richard Philipson, Ruth Coll, Vikram M. Narayan, F. Peter Treasure, Seppo Yla-Herttuala, Nigel R. Parker, Colin P. N. Dinney
Summary: The study demonstrates the efficacy of intravesical nadofaragene firadenovec, a novel therapy using a replication-deficient recombinant adenovirus, in patients with BCG-unresponsive non-muscle-invasive bladder cancer, with a favorable benefit:risk ratio. The treatment led to a complete response in a significant proportion of patients with carcinoma in situ, and the adverse events were generally mild, with no treatment-related deaths reported.
Article
Medicine, General & Internal
Jungyo Suh, Hyeong Dong Yuk, Chang Wook Jeong, Cheol Kwak, Hyeon Hoe Kim, Ja Hyeon Ku
Summary: This study found that preoperative pyuria, a history of upper urinary tract cancer, and tumor multiplicity are important predictors of BCG treatment unresponsiveness, with pyuria also being a significant prognostic factor for progression-free survival.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Pharmacology & Pharmacy
You Li, Shams F. Youssef, Asma B. M. Buanz
Summary: Bladder cancer is one of the top ten most commonly diagnosed cancers globally, with limited treatment options, but the development of intravesical combination therapies offers hope for overcoming treatment failures, although limitations still need to be addressed.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Seung-Woo Baek, Jeong-Yeon Mun, In-Hwan Jang, Gi-Eun Yang, Mi-So Jeong, Seon-Kyu Kim, Jong-Kil Nam, In-Sun Chu, Sun-Hee Leem
Summary: This study identifies the activation of Yes-associated protein 1 (YAP1) as a significant prognostic factor for bladder cancer progression and suggests its potential as a tool for immunotherapy selection.
Review
Oncology
Zein Alabdin Hannouneh, Amjad Hijazi, Alaa Aldeen Alsaleem, Siwan Hami, Nina Kheyrbek, Fadi Tanous, Karam Khaddour, Abdulfattah Abbas, Zuheir Alshehabi
Summary: High-risk non-muscle-invasive bladder cancer presents challenges due to resistance to BCG therapy and risk of progression to muscle-invasive bladder cancer. Finding alternative therapies to preserve the bladder is necessary.
Article
Oncology
Olga M. Pijpers, Kees Hendricksen, Hugh Mostafid, Florus C. de Jong, Marloes Rosier, Nikhil Mayor, Joep J. de Jong, Joost L. Boormans
Summary: This study aimed to evaluate the long-term efficacy of hyperthermic intravesical chemotherapy (HIVEC) as an alternative to radical cystectomy (RC) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients. The results showed that HIVEC resulted in a 2-year HG-RFS of 35% for BCG-unresponsive NMIBC patients without severe side-effects, suggesting that HIVEC could be a viable treatment option for patients who refuse or are unfit for RC.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Article
Cell Biology
Florus C. de Jong, Teemu D. Laajala, Robert F. Hoedemaeker, Kimberley R. Jordan, Angelique C. J. van der Made, Egbert R. Boeve, Deric K. E. van der Schoot, Bart Nieuwkamer, Emiel A. M. Janssen, Tokameh Mahmoudi, Joost L. Boormans, Dan Theodorescu, James C. Costello, Tahlita C. M. Zuiverloon
Summary: The recommended treatment for high-risk non-muscle-invasive bladder cancer patients is tumor resection followed by adjuvant Bacillus Calmette-Guerin (BCG) bladder instillations. However, only 50% of patients benefit from this therapy. Identifying tumors unlikely to respond to BCG can lead to alternative treatments for these patients.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Seon-Kyu Kim, Seong-Hwan Park, Yeong Uk Kim, Young Joon Byun, Xuan-Mei Piao, Pildu Jeong, Kyeong Kim, Hee Youn Lee, Sung Pil Seo, Ho Won Kang, Won Tae Kim, Yong-June Kim, Sang-Cheol Lee, Sung-Kwon Moon, Yung Hyun Choi, Wun-Jae Kim, Seon-Young Kim, Seok Joong Yun
Summary: A molecular signature, MSP888, has been identified for Non-muscle-invasive bladder cancer (NMIBC) that can predict heterogeneity and responses to Bacillus Calmette-Guerin (BCG) therapy. This signature includes three distinct molecular subtypes, with DP.BCG+ related to progression and response to BCG treatment, and REC.BCG+ related to recurrence and response to BCG treatment. These findings enhance understanding of NMIBC prognosis and the effectiveness of BCG therapy, potentially improving clinical practice.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Hannah Slovacek, Jerry Zhuo, Jennifer M. Taylor
Summary: NMIBC is a heterogeneous malignancy with high recurrence and progression rates, necessitating uniform recommendations for diagnosis and management. Guidelines worldwide have adopted risk-stratification at diagnosis to provide evidence-based treatment and surveillance recommendations. Improved endoscopic technologies enhance NMIBC detection and decrease recurrence.
CURRENT ONCOLOGY REPORTS
(2021)
Article
Urology & Nephrology
Justin T. Matulay, Roger Li, Patrick J. Hensley, Nathan A. Brooks, Vikram M. Narayan, H. Barton Grossman, Neema Navai, Colin P. N. Dinney, Ashish M. Kamat
Summary: The study retrospectively reviewed data of patients with nonmuscle-invasive bladder cancer treated with intravesical bacillus Calmette-Guerin at a tertiary cancer center. Results showed that these patients had improved survival and progression rates compared to previous studies, providing valuable benchmarks for clinical trial design.
JOURNAL OF UROLOGY
(2021)
Article
Oncology
Niannian Ji, Meijun Long, Andreu Garcia-Vilanova, Russell Ault, Juan Moliva, Kizil A. Yusoof, Neelam Mukherjee, Tyler J. Curiel, Hong Dixon, Jordi B. Torrelles, Robert S. Svatek
Summary: The study found that selectively delipidated bacillus Calmette et Guerin (BCG) has a good effect in treating bladder cancer and can enhance the function and cytotoxicity of immune cells. This research provides a new treatment option for patients with BCG-intolerant non-muscle invasive bladder cancer (NMIBC).
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Htoo Zarni Oo, Roland Seiler, Peter C. Black, Mads Daugaard
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2020)
Article
Oncology
Jose Batista da Costa, Ewan A. Gibb, Timo K. Nykopp, Miles Mannas, Alexander W. Wyatt, Peter C. Black
Summary: This review discusses the inter- and intratumor heterogeneity in muscle invasive bladder cancer (MIBC) and explores the clinical implications of this heterogeneity for biomarker-driven strategies and the development of new therapies. Molecular subtyping and genomic alterations may help explain variations in treatment response among patients.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Editorial Material
Urology & Nephrology
Roland Seiler, Alexander W. Wyatt, Peter C. Black
Editorial Material
Urology & Nephrology
Marco Moschini, Shahrokh F. Shariat, Peter Black, Ashish M. Kamat, Armando Stabile, Xavier Cathelineau, Wassim Kassouf, Bernard H. Bochner, Evanguelos Xylinas, Morgan Roupret, Stephen A. Boorjian, James W. Catto, Rafael Sanchez-Salas
Article
Urology & Nephrology
Miles P. Mannas, Taeweon Lee, Connor M. Forbes, Tracey Hong, Andrea Bisaillon, Martin E. Gleave, Alan So, Kelly Mayson, Peter C. Black
WORLD JOURNAL OF UROLOGY
(2020)
Article
Urology & Nephrology
Paolo Gontero, Francesca Pisano, Joan Palou, Steven Joniau, Maarten Albersen, Renzo Colombo, Alberto Briganti, Federico Pellucchi, Oscar Rodriguez Faba, Bas W. van Rhijn, Elies Fransen van de Putte, Marko Babjuk, Hanz Martin Fritsche, Roman Mayr, Peter Albers, Gunter Niegisch, Julien Anract, Alexandra Masson-Lecomte, Alexandre De la Taille, Morgan Roupret, Benoit Peyronnet, Tomaso Cai, Alfred J. Witjes, Max Bruins, Jack Baniel, Roy Mano, Alberto Lapini, Francesco Sessa, Jaques Irani, Maurizio Brausi, Arnulf Stenzl, Jeffrey R. Karnes, Douglas Scherr, Padraic O'Malley, Benjamin Taylor, Shahrokh F. Shariat, Peter Black, Hamidreza Abdi, Vsevolod B. Matveev, Olga Samuseva, Dipen Parekh, Mark Gonzalgo, Malte W. Vetterlein, Atiqullah Aziz, Margit Fisch, James Catto, Karl H. Pang, Evanguelos Xylinas, Michael Rink
WORLD JOURNAL OF UROLOGY
(2020)
Article
Oncology
Anna J. Black, Homayoun Zargar, Kamran Zargar-Shoshtari, Adrian S. Fairey, Laura S. Mertens, Colin P. Dinney, Maria C. Mir, Laura-Maria Krabbe, Michael S. Cookson, Niels-Erik Jacobsen, Joshua Griffin, Jeffrey S. Montgomery, Nikhil Vasdev, Evan Y. Yu, Evanguelos Xylinas, Nicholas J. Campain, Wassim Kassouf, Marc A. Dall'Era, Jo-An Seah, Cesar E. Ercole, Simon Horenblas, John S. McGrath, Jonathan Aning, Shahrokh F. Shariat, Jonathan L. Wright, Andrew C. Thorpe, Todd M. Morgan, Jeff M. Holzbeierlein, Trinity J. Bivalacqua, Scott North, Daniel A. Barocas, Yair Lotan, Petros Grivas, Andrew J. Stephenson, Jay B. Shah, Bas W. van Rhijn, Philippe E. Spiess, Siamak Daneshmand, Srikala S. Sridhar, Peter C. Black
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2020)
Article
Urology & Nephrology
Tuomas Jalanko, Joep J. de Jong, Ewan A. Gibb, Roland Seiler, Peter C. Black
CURRENT UROLOGY REPORTS
(2020)
Correction
Urology & Nephrology
Tuomas Jalanko, Joep J. de Jong, Ewan A. Gibb, Roland Seiler, Peter C. Black
CURRENT UROLOGY REPORTS
(2020)
Editorial Material
Multidisciplinary Sciences
Mathieu Roumiguie, Alberto Contreras-Sanz, Gunjan Kumar, Peter C. Black
NATURE COMMUNICATIONS
(2021)
Review
Urology & Nephrology
Moritz Maas, Tilman Todenhoefer, Peter C. Black
Summary: The detection of bladder cancer through urine markers has been a long-standing research topic. While the idea of urine as a vector of tumor information is attractive, the use of urine markers in clinical practice is currently limited despite the availability of numerous markers and efforts in research and development. Prospective trials are underway to increase the evidence on urinary biomarkers in bladder cancer and promote their implementation in guidelines. This Review provides a comprehensive overview of current status, limitations, and future perspectives of urine markers.
NATURE REVIEWS UROLOGY
(2023)
Article
Urology & Nephrology
Peter C. Black, Catherine M. Tangen, Parminder Singh, David J. McConkey, M. Scott Lucia, William T. Lowrance, Vadim S. Koshkin, Kelly L. Stratton, Trinity J. Bivalacqua, Wassim Kassouf, Sima P. Porten, Rick Bangs, Melissa Plets, Ian M. Thompson, Seth P. Lerner
Summary: This study evaluated the efficacy and safety of atezolizumab in BCG-unresponsive high-risk NMIBC patients who were ineligible for or declined surgery. The results showed that atezolizumab had a good pathological complete response rate in patients with carcinoma in situ, and some patients had durable responses. However, there were severe treatment-related adverse events in some patients.
Article
Oncology
Siamak Daneshmand, Clint Cary, Timothy Masterson, Lawrence Einhorn, Nabil Adra, Stephen A. Boorjian, Christian Kollmannsberger, Anne Schuckman, Alan So, Peter Black, Aditya Bagrodia, Eila Skinner, Mehrdad Alemozaffar, Timothy Brand, Scott Eggener, Phillip Pierorazio, Kelly Stratton, Lucia Nappi, Craig Nichols, Chunqiao Luo, Ming Li, Brian Hu
Summary: This study aimed to investigate the efficacy of RPLND as a first-line treatment for testicular seminoma with clinically low-volume retroperitoneal lymphadenopathy. The results showed that the 2-year recurrence-free survival rate was 81%, the recurrence rate was 22%, and the 2-year overall survival rate was 100%. The study concluded that RPLND is a viable treatment option with low long-term morbidity.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Omid Yassaie, Cyrus Chehroudi, Peter C. Black
Summary: Non-muscle invasive bladder cancer is traditionally managed with transurethral resection and intravesical therapy, but alternative treatment options with acceptable oncological outcomes are critical for BCG-unresponsive patients to preserve the bladder.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Meeting Abstract
Urology & Nephrology
Tetsutaro Hayashi, Kenichiro Ikeda, Roland Seiler, Robert H. Bell, Susan Ettinger, Kendric Wang, Htoo Zarni Oo, Hamidreza Abdi, Wolfgang Jaeger, Tilman Todenhoefer, Colin Collins, Akio Matsubara, Peter C. Black
JOURNAL OF UROLOGY
(2019)